

## Board changes for SciGen Limited

**Sydney, Australia. October 21<sup>st</sup>, 2005.** ASX listed (ASX:SIE) and Singapore-based biopharmaceutical company SciGen Ltd today announced that Dr Colin Goldschmidt had decided against standing for re-election to the Board of Directors of SciGen at the forthcoming Annual General Meeting of the Company, after 6 years in office.

Dr. Goldschmidt held one of two Board positions allocated to Sonic Healthcare, which spun out most of its SciGen shareholding in 2002. His board position was due for re-election at the Annual General Meeting on 21 November 2005. Dr. Goldschmidt will vacate his office as a director of SciGen from October 21<sup>st</sup>, 2005.

Mr. Chris Wilks also with Sonic Healthcare will retire as a non-executive director of SciGen retiring from his office effective from October 21<sup>st</sup>, 2005.

Both Dr. Goldschmidt and Mr. Wilks cited their time commitments to Sonic Healthcare as the reason for their decision.

On behalf of the Board, Mr Paul Freiman, Chairman of SciGen Ltd, thanked Dr Goldschmidt and Mr Wilks for their contribution to SciGen over the years. Mr. Saul Mashaal, Executive Vice Chairman, Founder & CEO added "We are well on our way to restructuring the Board which will ensure that SciGen continues to get the support and guidance it needs for a strong future."

**Sonic Healthcare currently owns 8.75% of SciGen.**

### Further information:

Investor Relations and Media	Company
Rebecca Wilson Buchan Consulting +61 2 9237 2800 +61 417 382 391 (mobile) rwilson@bcg.com.au	Saul Mashaal Executive Vice Chairman, Founder & CEO SciGen Ltd. + 61 2 9234 1700 +65 9630 5691 (Mobile)